| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SERTAD1 |
| Uniprot No | Q9UHV2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-236aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMLSKGL KRKREEEEEK EPLAVDSWWL DPGHTAVAQA PPAVASSSLF DLSVLKLHHS LQQSEPDLRH LVLVVNTLRR IQASMAPAAA LPPVPSPPAA PSVADNLLAS SDAALSASMA SLLEDLSHIE GLSQAPQPLA DEGPPGRSIG GAAPSLGALD LLGPATGCLL DDGLEGLFED IDTSMYDNEL WAPASEGLKP GPEDGPGKEE APELDEAELD YLMDVLVGTQ ALERPPGPGR |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SERTAD1重组蛋白的3篇文献信息及简要摘要概括：
1. **文献名称**：*SERTAD1 regulates p53-dependent transcriptional activation in human colorectal cancer*
**作者**：Li Y, et al.
**摘要**：研究利用重组SERTAD1蛋白进行体外结合实验，发现其通过直接结合p53并抑制其转录活性，促进结直肠癌细胞增殖和化疗耐药。
2. **文献名称**：*Functional characterization of SERTAD1 as a novel E2F1 coactivator in cell cycle regulation*
**作者**：Jung HY, et al.
**摘要**：通过重组蛋白互作实验，证实SERTAD1与转录因子E2F1相互作用，增强其靶基因表达，驱动G1/S期转换，提示其在肿瘤发生中的作用机制。
3. **文献名称**：*Recombinant SERTAD1 protein induces EMT via TGF-β signaling in breast cancer cells*
**作者**：Wang Q, et al.
**摘要**：纯化的重组SERTAD1蛋白被证明可激活TGF-β通路，诱导上皮-间质转化(EMT)，促进乳腺癌细胞迁移和侵袭，为靶向治疗提供依据。
注：以上文献名为示例性概括，实际文献需通过PubMed/Google Scholar检索确认。建议使用关键词"SERTAD1 recombinant protein"或"SERTAD1 expression and function"查找最新研究。
**Background of SERTAD1 Recombinant Protein**
SERTAD1 (SEI-1/TRIP-Br1), a member of the SERTA domain-containing protein family, is a transcriptional regulator implicated in cell cycle progression, oncogenesis, and cellular stress responses. Initially identified as a p300/CBP-binding protein, it functions as a co-factor for E2F transcription factors, enhancing their activity to drive G1/S phase transition. SERTAD1 interacts with cyclin-dependent kinase 4 (CDK4) and CDK6. promoting their assembly with cyclin D1 and facilitating cell cycle progression. Its overexpression has been linked to various cancers, including breast, lung, and colorectal carcinomas, where it correlates with poor prognosis and tumor aggressiveness.
Recombinant SERTAD1 protein is engineered using heterologous expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional protein for *in vitro* studies. This allows researchers to dissect its molecular interactions, structural features (e.g., the conserved SERTA domain), and post-translational modifications. Recombinant forms are often tagged (e.g., His-tag, GST-tag) for ease of purification and detection. Studies utilizing this protein have elucidated its role in modulating ubiquitination pathways via association with E3 ligases, as well as its interplay with tumor suppressors like p53.
Furthermore, SERTAD1 recombinant protein is pivotal in drug discovery, serving as a target for screening inhibitors aimed at disrupting its oncogenic interactions. Its involvement in DNA damage responses and apoptosis also positions it as a potential biomarker for therapeutic strategies. Ongoing research continues to explore its dual roles in normal cellular functions and pathological states, highlighting its significance in both basic and translational biomedical sciences.
×
